dc.contributor.author |
Asnake, Molla |
|
dc.contributor.author |
Henock, Andualem |
|
dc.contributor.author |
Abayneh, Menigistu |
|
dc.contributor.author |
Getu, Shimelis |
|
dc.contributor.author |
Hailemariam5, Shewangizaw |
|
dc.contributor.author |
Endalkachew, Biruk |
|
dc.contributor.author |
Zerihun, Dessalegn |
|
dc.date.accessioned |
2025-01-27T11:35:23Z |
|
dc.date.available |
2025-01-27T11:35:23Z |
|
dc.date.issued |
2022-12-20 |
|
dc.identifier.citation |
https://journals.sagepub.com/doi/full/10.1177/2050313X221094076 |
en_US |
dc.identifier.uri |
http://repository.mtu.edu.et/xmlui/handle/123456789/224 |
|
dc.description.abstract |
Among drug-related complications, drug-related nephrotoxicity is the commonest. It is the cause for 7% of all drug-related toxicities among inpatients and accounts for 20% to 30% of acute renal failure. Acute interstitial nephritis is one of the drug-related adverse reactions and occurs due to a drug-related type 4 hypersensitivity reaction. In this case report, we reported acute interstitial nephritis that causes acute renal failure (acute kidney injury) in a patient taking Prothionamide therapy. This drug-related side effect had not been reported. In this case report, we report a patient who develops fatigability, rash, and intermittent fever after 14 days of taking the drug Prothionamide. The main aims of this case report are to use it as a pharmacovigilance report for drug-producing companies and to consider a further study on this side effect. It is also an alert for clinicians to consider this side effect when patients develop acute interstitial nephritis while taking Prothionamide. |
en_US |
dc.description.sponsorship |
Mizan-Tepi University |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
SAGE Open Medical Case Reports |
en_US |
dc.subject |
Prothionamide, acute interstitial nephritis, drug-induced acute interstitial nephritis |
en_US |
dc.title |
Acute interstitial nephritis with Prothionamide |
en_US |
dc.type |
Other |
en_US |